《新股消息》雲頂新耀(01952.HK)今日起招股 入場費27,777元
生物製藥公司雲頂新耀(01952.HK)公布招股詳情,計劃發行6,354.7萬股,當中約10%在港公開發售,集資最多34.95億,招股價介乎50至55元,一手500股,入場費為27,777.12元。由今日(25日)至下周三(30日)公開招股,預計於10月9日上市。高盛及美銀證券為聯席保薦人。
以招股價中位數52.5元計,公司預計集資淨額為31.32億元,當中將60%用於為集團四款支柱產品的進行中及計劃臨床試驗、登記備案準備及有關商業化的其他步驟或活動提供資金;15%為其他候選藥物的進行中及計劃臨床試驗、登記備案準備及潛在商業化提供資金;15%用於業務發展活動及擴展藥品管線提供資金;以及10%用作營運資金以及一般及行政用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.